Impact of Clopidogrel Stop Interval on Major Adverse Bleeding Events in Cardiac Surgery

Bright Huo, BScPharm, a Gregory M. Hirsch, MD, b Steve Doucette, MSc, b Christine R. Herman, MD, MSc, FRCSC, b Ryan Gainer, MSc, b and Ahmed T. Mokhtar, MBBS, FRCP,C,d

a Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
b Division of Cardiac Surgery, Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada
c Division of Cardiology, Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
d Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

ABSTRACT

Background: Major societal guidelines recommend a 5-day stop interval before cardiac surgery for patients with acute coronary syndrome receiving clopidogrel. Yet, many such patients present with high acuity, generating surgeon inclination toward use of shorter stop intervals. Thus, this study aimed to determine the impact of the duration and timing of the interval of clopidogrel cessation on adverse bleeding events.

Methods: Patients who underwent cardiac surgery between 2009 and 2016 at a tertiary-care centre were included in this retrospective cohort study. Multivariable logistic regression models adjusted for clopidogrel stop interval, age, urgency of procedure, and procedure type were used to quantify the effect of clinically relevant baseline demographic characteristics on incidence of massive transfusion as well as hemorrhagic complication outcomes.

P2Y12 inhibitors are the standard of care for patients presenting with acute coronary syndrome (ACS), as these inhibitors reduce major adverse cardiovascular events.1-3 However, many ACS patients require in-hospital coronary artery bypass graft (CABG) surgery; in this context, these agents increase the risk of bleeding, re-exploration, and higher transfusion rates, with adverse perioperative outcomes, including mortality and prolonged ventilation.4-14

Clinical practice guidelines recommend a 5-day waiting period preoperatively before CABG surgery, to reduce these risks.15-18 Although the European Society of Cardiology (ESC) firmly recommends a 5-day stop interval, the Canadian Cardiovascular Society (CCS)/Canadian Association of Interventional Cardiology (CAIC) and American Heart Association (AHA)/American College of Cardiology (ACC) weakly recommend a shorter stop interval for those requiring urgent surgical care.15,16,18 We and others have published observational studies indicating that a shorter washout period is reasonable, with some evidence that bleeding outcomes for patients with 3-day stop intervals are comparable to those with 5-day stop intervals.6,7,12,19 Moreover, adherence to a 5-day stop interval is uncommon in clinical practice, especially in the context of a recent ACS event, owing to patient acuity as
Results: A total of 5748 patients underwent cardiac surgery. In this cohort, 1743 patients (30.3%) received clopidogrel preoperatively, and 884 (50.7%) of these patients discontinued clopidogrel 5 days before presenting to the operating room. The administration of clopidogrel 1-2 days before surgery (odds ratio 1.97; 95% confidence interval: 1.18 to 3.29) was an independent predictor for massive transfusions and hemorrhagic complications (odds ratio 1.85; 95% confidence interval: 1.01 to 3.37). The 3-4 day group did not have an increased risk of major bleeding complications. The risk for both massive transfusions and hemorrhagic complications also increased with the urgency and complexity of surgery.

Conclusion: A clopidogrel stop interval of 3-4 days preoperatively was not associated with an increased risk for major bleeding complications.

well as bed-occupancy pressures. Taken together, these findings reflect uncertainty about the necessity of a 5-day stop interval, a duration that may impede timely revascularization. Thus, this study aimed to determine the impact of the length of the interval for cessation of clopidogrel on adverse bleeding events, need for massive transfusion, mortality, and major adverse cardiovascular events.

Methods and Materials

Patient population

The study population included patients who underwent cardiac surgical procedures between April 2009 and April 2016 at the Queen Elizabeth II Health Sciences Centre (QEII HSC) in Halifax, Nova Scotia, Canada. The QEII HSC is the sole provider of cardiac surgical care for Nova Scotia. Procedure types included isolated CABG, isolated valve repair or replacement, or combined CABG and single-valve procedures. Patients were excluded if they underwent transplantation, multiple-valve procedures, transcardiac aortic valve replacement, or treatment with ticagrelor, and if they had a history of trauma. Elective, urgent (defined as the need for intervention within 24 hours), and emergent procedures were also included. Cardiac surgery was performed with cardiopulmonary bypass, and anticoagulation was achieved using intravenous heparin given at a dose of 400 IU/kg, with a target activated clotting time > 450 seconds. Antifibrinolytic agents were used routinely and consisted mainly of tranexamic acid. Intermittent cold-blood cardioplegia was delivered in an antegrade or retrograde fashion, based on surgeon preference. Protamine sulfate was given for reversal of heparin effects in all patients.

Data source

Data were obtained from the Maritime Heart Centre Cardiac Surgery Registry. This registry is a detailed, prospectively collected clinical database containing perioperative data on all cardiac surgery cases performed from March 1995 to present at the QEII HSC. We have previously published a similar report utilizing the same data source. The QEII HSC is the only cardiac surgical centre for the province of Nova Scotia, serving a base population of nearly one million. Moreover, by linking our observational data with a laboratory information system that is run by the Department of Pathology and Laboratory Medicine at the QEII HSC, comprehensive perioperative information on the timing, amount, type, and number of products transfused for each patient was obtained.

Primary outcome

The primary end point was the development of adverse bleeding events, including massive transfusions and hemorrhagic complications. Massive transfusion was defined as any transfusion of > 4 units of packed red blood cells (PRBCs) either intraoperatively or within the first 48 hours postoperatively. Previous literature defines massive transfusion as the use of ≥ 4 units of PRBCs. Hemorrhagic complications were defined as either cardiac tamponade, as established by bedside echocardiography, or re-exploration for bleeding.

Secondary outcomes

Secondary outcomes included the need for transfusion of any blood products intraoperatively or within the first 48 hours postoperatively. Transfusion parameters, including number of units, and type and timing of transfusion, were reported. Major adverse clinical events of interest included mortality, prolonged mechanical ventilation beyond 24 hours, and deep sternal wound infection.

Variable selection and analysis

Other preoperative clinical characteristics of interest included age, sex, aspirin use, clopidogrel stop intervals, hemoglobin, body mass index, urgency, serum creatinine level,
dialysis status, chronic obstructive pulmonary disease, diabetes status, peripheral and/or cerebral vascular disease, and ejection fraction. Individual procedure types were categorized as isolated CABG, isolated aortic or mitral valve replacement or repair, or combined coronary artery bypass with single valve replacement.

**Statistical analysis**

Baseline demographic information and pretreatment clinical measures were summarized using descriptive statistics. Categorical data were presented as frequencies and percentages. Continuous data were presented as mean ± standard deviation. Comparisons across categories of the timing of clopidogrel discontinuation were made using the $\chi^2$ test and analysis of variance, as appropriate. Outcome data were summarized as frequencies with percentages and compared across timing categories and transfusion status using Fisher’s exact tests. Transfusion outcomes were also summarized across categories of the timing of clopidogrel stop intervals, including < 24 hours, 1-2 days, 2-3 days, 3-4 days, 4-5 days, and > 5 days.

Multivariable logistic regression analysis was used to quantify the relationship between clinically relevant baseline demographic characteristics and massive transfusion as well as hemorrhagic complication outcomes. Patient characteristics in the adjusted model identified a priori include the following: clopidogrel stop interval, acetylsalicylic acid status, age at time of surgery, sex, preoperative hemoglobin level, body mass index, urgency of procedure, kidney function, ejection fraction, procedure type, platelet count, and status of diabetes, peripheral vascular diseases, cerebrovascular disease, and chronic obstructive pulmonary disease. All statistical analysis was performed using SAS software, version 9.4 (SAS Institute, Cary, NC).

**Ethics**

This study was conducted with the full approval of the institutional (Nova Scotia Health Authority) research ethics board (file no. 1023270). The requirement to obtain informed consent was waived under Section 2.1c of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. All personal identifiers were stripped prior to data analysis, to ensure patient anonymity and confidentiality. The research reported in this paper adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

**Results**

**Study population and descriptive analysis**

A total of 5748 patients were included in our study. The mean age was 68 years (standard deviation 10.2), and 1423 patients (24.8%) were female. A total of 1743 patients (30.3%) received clopidogrel preoperatively. Among these, 884 (50.7%) had discontinued clopidogrel 5 days preoperatively (Table 1). Overall, 3910 patients (68.0%) underwent CABG surgery, 681 (11.8%) underwent isolated valve repair or replacement, and 1157 (20.1%) underwent combined CABG and valve surgery. Among the patients who discontinued clopidogrel before surgery, 54 patients (0.9%) stopped within 24 hours, 211 (3.7%) stopped 1-2 days before surgery, 199 (3.5%) stopped 2-3 days before surgery, 191 (3.3%) stopped 3-4 days before surgery, 229 (4.0%) stopped 4-5 days before surgery, and 859 (14.9%) discontinued clopidogrel > 5 days before surgery. As demonstrated in Table 1, patients who discontinued clopidogrel 1-2 days preoperatively were more likely to be emergent or urgent cases and have a hemoglobin level < 130g/L. Those receiving clopidogrel < 24 hours and 1-2 days before surgery were more likely to have a high serum creatinine level, renal failure, and a low ejection fraction, and they were more likely to receive preoperative hemoglobin and platelets. Patients in these 2 groups were also more often referred for emergent or urgent care (Table 1). Patients who received clopidogrel 3-4 days before surgery were more likely to be elective cases with higher preoperative hemoglobin levels, and they demonstrated less need for preoperative platelets. Those not prescribed clopidogrel were more likely to receive combination CABG and valve surgery.

**Unadjusted intraoperative and postoperative outcomes**

In the study population, 159 patients (9.1%) received a massive transfusion, and 95 patients (5.5%) experienced hemorrhagic complications (Table 2). Among those discontinuing clopidogrel within 24 hours before surgery or 1-2 days before surgery, 12 patients (22.2%) and 36 patients (17.1%) received a massive transfusion, and 3 patients (5.6%) and 21 patients (10%) patients experienced hemorrhagic complications, respectively. The rates of mortality, prolonged ventilation, sepsis, pneumonia, and bleeding were significantly higher among those who received clopidogrel either within 24 hours or 1-2 days preoperatively. Similarly, these postoperative outcomes were more common among those who received any transfusion(s), compared with those who were not transfused (Table 3).

**Intraoperative and postoperative transfusions**

Of all transfusion products, patients received a greater number of units of PRBCs, compared with the units of platelets and fresh-frozen plasma (FFP; Table 4). Patients receiving clopidogrel within 24 hours of surgery received the most units of transfusion products, including PRBCs (mean: 2.2 ± 4.0 units), platelets (mean: 0.5 ± 1.2 units), and FFP (mean: 0.6 ± 1.2 units). Comparably, patients dosed with clopidogrel 1-2 days before surgery were more commonly transfused with PRBCs (mean: 1.9 ± 3.7 units), platelets (mean: 0.4 ± 0.9 units), and FFP (mean: 0.5 ± 1.7 units). Those dosed with clopidogrel 1-2 days before surgery received more than twice the number of units of PRBCs, platelets, and FFP, compared with those not receiving clopidogrel, and they also had a higher transfusion rate overall. The cessation of clopidogrel 2-3 days before surgery achieved a rate of transfusion of 31.2%, similar to the percentage for those who stopped clopidogrel 4-5 days preoperatively. The average number of units of PRBCs, platelets, and FFP transfused was greater during surgery than postoperatively, across all groups.

**Independent predictors of bleeding**

The administration of clopidogrel 1-2 days before surgery (odds ratio [OR] 1.97; 95% confidence interval [CI]: 1.18 to
3.29; \( P = 0.01 \) was an independent predictor for massive transfusion in multivariable logistic regression analysis (Fig. 1). Other independent risk factors for massive transfusion included a low preoperative hemoglobin level, greater urgency of surgery, decreased renal function, a low ejection fraction, and peripheral vascular disease.

Clopidogrel administration 1-2 days before surgery (OR 1.85; 95% CI: 1.01 to 3.37; \( P = 0.046 \)) was an independent predictor of hemorrhagic complications, defined as cardiac tamponade or re-exploration for bleeding (Fig. 1). The risk for hemorrhagic complications also increased with the use of aspirin, female gender, greater urgency of surgery, decreased renal function, and greater complexity of surgery. Beyond 3 days of clopidogrel administration, no increased risk of massive transfusion nor hemorrhagic complications were demonstrated.

Patients receiving clopidogrel were at an increased risk for receiving any transfusions at 1-2 days (OR 1.98; 95% CI: 1.37 to 2.86; \( P = 0.0003 \)) and 4-5 days (OR 1.75; 95% CI 1.22 to 2.50; \( P = 0.0023 \)).

### Discussion

This study assessed the relationship between a clopidogrel stop interval and major bleeding risk among 5748 patients receiving isolated CABG surgery, isolated valve repair or replacement, or combined CABG and valve procedures. We demonstrate that patients receiving clopidogrel 1-2 days before surgery experienced significantly more massive transfusions (transfusion of > 4 units of PRBCs) and hemorrhagic complications, defined as cardiac tamponade and re-exploration for bleeding. Multivariate analysis revealed that, after controlling for other relevant risk factors, patients dosed with clopidogrel 1-2 days before surgery were at a roughly 2-fold increased risk for both massive transfusions and hemorrhagic complications.

### Clopidogrel stop interval and bleeding outcomes

The American College of Cardiology and the American Heart Association recommend that clopidogrel be stopped for 5 days before elective CABG surgery and for at least 24 hours before urgent CABG surgery. This recommendation stems from 3 studies, including the Study of Platelet Inhibition and Patient Outcomes (PLATO) trial, which noted that among a subgroup of 627 patients, the drop in hemoglobin decreased in those receiving clopidogrel > 5 days before surgery. Correspondingly, Berger et al. found that among 396 patients, those receiving clopidogrel within 5 days showed an increased risk for major bleeding and reoperation for bleeding complications. The guidelines also cite Hongo and
Table 2. Unadjusted outcomes and timing of clopidogrel discontinuation prior to surgery

| Variable                          | Timing of clopidogrel discontinuation prior to surgery, d |
|-----------------------------------|----------------------------------------------------------|
|                                   | < 24 h | 1–2 | 2–3 | 3–4 | 4–5 | > 5 | No clopidogrel | P       |
| Hemorrhagic complications         | 3 (5.6) | 21 (10) | 16 (8) | 10 (5.2) | 7 (3.1) | 38 (4.4) | 151 (3.8) | 0.0001  |
| Massive transfusion               | 12 (22.2) | 36 (17.1) | 21 (10.6) | 9 (4.7) | 16 (7) | 65 (7.6) | 250 (6.2) | < 0.0001 |
| Mortality                         | 5 (9.3) | 19 (9) | 11 (5.5) | 6 (3.1) | 9 (3.9) | 23 (2.7) | 82 (2.1) | < 0.0001 |
| Prolonged ventilation             | 30 (55.6) | 73 (34.6) | 36 (18.1) | 27 (14.1) | 43 (18.8) | 134 (15.6) | 588 (14.7) | < 0.0001 |
| Pneumonia                         | 10 (18.5) | 27 (12.8) | 13 (7.5) | 8 (4.2) | 14 (6.1) | 51 (5.9) | 255 (6.4) | < 0.0001 |
| Bleeding                          | 8 (14.8) | 24 (11.4) | 20 (10.1) | 13 (6.8) | 13 (5.7) | 61 (7.1) | 234 (5.8) | 0.0011  |
| Sternal wound infection           | 1 (1.9) | 3 (1.4) | 2 (1) | 0 (0) | 3 (1.3) | 7 (0.8) | 37 (0.9) | 0.7017  |

Values are n (%), unless otherwise indicated.

Table 3. Unadjusted outcomes and transfusion status

| Variable                          | Transfusion (n = 1612) | No transfusion (n = 4136) | P       |
|-----------------------------------|------------------------|---------------------------|---------|
| Hemorrhagic complications         | 188 (11.7)             | 58 (1.4)                  | < 0.0001|
| (tamponade/redo sternotomy)       |                        |                           |         |
| Massive transfusion               | 409 (25.4)             | 0 (0)                     | < 0.0001|
| Mortality                         | 100 (6.2)              | 59 (1.3)                  | < 0.0001|
| Prolonged ventilation             | 568 (35.2)             | 363 (8.8)                 | < 0.0001|
| Sepsis                            | 69 (4.3)               | 21 (0.5)                  | < 0.0001|
| Pneumonia                         | 231 (14.3)             | 149 (3.6)                 | < 0.0001|
| Bleeding                          | 254 (15.8)             | 119 (2.9)                 | < 0.0001|
| Sternal wound infections           | 34 (2.1)               | 19 (0.5)                  | < 0.0001|

Values are n (%), unless otherwise indicated. Massive transfusion is defined as ≥ 4 units transfused perioperatively.

The multivariate model indicated that patients receiving clopidogrel 1-2 days before surgery were at nearly a 2-fold increased risk for major transfusions and hemorrhagic complications. Similarly, Ascione and colleagues found that clopidogrel administration within 48 hours of surgery produced higher rates of transfusion and adverse outcomes. The risk for both massive transfusion and hemorrhagic complications was also independently increased by increased urgency and complexity of surgery, as we previously noted in a smaller study. Our findings suggest that transfusion rates increase as the preoperative clopidogrel stop interval is shortened. However, this increased risk for massive transfusions is less pronounced from 3-4 days of clopidogrel discontinuation and upward. The multivariate model revealed no increased risk for either massive transfusions or hemorrhagic complications in the group with a preoperative 3-4-day stop interval. Similarly, one study of 7048 patients undergoing CABG surgery found that a preoperative clopidogrel stop interval of 3 days produced rates of re-exploration for major bleeding comparable to those obtained with a 5-day clopidogrel stop interval. Further, Firanescu and colleagues found that the level of blood loss and use of blood products among patients stopping clopidogrel 3 days preoperatively were comparable to that among those discontinuing clopidogrel 5 days before surgery. Although we did not demonstrate a statistically significant increase in major bleeding at 2-3 days, the OR was very close to unity for hemorrhagic complications (OR 1.81; 95% CI: 0.98-3.36). This result suggests that bleeding complications remain a concern at this time interval and should factor into management decisions.
Mortality, prolonged ventilation, transfusions

Seese et al. recently reported that clopidogrel use before CABG surgery increased the rate of prolonged ventilation. In our study, both groups that received clopidogrel within either 24 hours or 1-2 days of surgery demonstrated an increased rate of transfusions, prolonged ventilation, and greater mortality, compared with all other subgroups. Similarly, we have previously reported that clopidogrel administration within either 24 hours or 2 days of surgery increased the rate of transfusions, prolonged ventilation, and mortality, providing further support for postponing surgery for at least 3 days between clopidogrel dosage and surgical intervention. Our study further suggests that an increased number of units are transfused intraoperatively, rather than postoperatively, among patients dosed with clopidogrel within 1-2 days of surgery, the first report of such a finding to our knowledge. However, after multivariable analysis, patients were at an increased risk for receiving any transfusion when administered clopidogrel either 1-2 days or 4-5 days preoperatively. Interestingly, patients who had a 4-5 day preoperative stop interval were neither more acute nor more complex in terms of surgery performed. Similarly, patients in this 4-5 day group were not more comorbid, nor older, and they did not have a lower mean hemoglobin level or platelet count. Thus, we are at a

Table 4. Transfusions and timing of clopidogrel discontinuation prior to surgery

| Timing of clopidogrel discontinuation prior to surgery, d | Any transfusion, n (%) | PRBCs | Postoperative | Amount transfused |
|----------------------------------------------------------|------------------------|-------|---------------|------------------|
| < 24 h                                                   | 27 (50)                | 2.2 (4) | 0.9 (2.2) | 644 (1152.1) |
| 1-2                                                      | 102 (48.3)             | 1.9 (3.7) | 0.6 (1.8) | 541.6 (1067.4) |
| 2-3                                                      | 62 (31.2)              | 1.1 (2.7) | 0.5 (2)    | 315.1 (784.5) |
| 3-4                                                      | 46 (24.1)              | 0.6 (1.6) | 0.2 (0.7)  | 164.5 (448.2) |
| 4-5                                                      | 76 (33.2)              | 0.4 (1.2) | 0.4 (1.4)  | 251.7 (621.1) |
| > 5                                                      | 243 (28.3)             | 0.5 (1.3) | 0.3 (1.2)  | 240.3 (616.3) |
| No clopidogrel                                           | 1056 (26.4)            | 0.8 (2.1) | 0.3 (1.4)  | 219 (593)   |

Values are mean (standard deviation), unless otherwise indicated.

FFP, fresh-frozen plasma; PRBCs, packed red blood cells.

Figure 1. Multivariable predictors of massive transfusion and hemorrhagic complications post--cardiac surgery include the use of clopidogrel 1-2 days before surgery. CI, confidence interval; OR, odds ratio.
loss to explain the increased transfusion rates during this timeframe.

Limitations

We acknowledge that this study has limitations, including its susceptibility to confounding factors secondary to its retrospective approach. Furthermore, information about ACS presentation type was lacking. Although we did control for urgency of surgery, confounding by indication may have resulted in sicker patients receiving surgery earlier, which may correlate with bleeding complications and mortality, and this remains a limitation of this study. Additionally, statistical power was limited in the subgroup of patients receiving clopidogrel within 24 hours of cardiac surgery, although previous literature suggests that outcomes for major bleeding are likely similarly increased during this timeframe. The impact on bleeding outcomes of variability among surgeons and their approach to the timing of cardiac surgery among patients receiving clopidogrel was not captured in this study. Our centre performs very few off-pump CABG procedures; thus, the safety of clopidogrel stop intervals in patients revascularized with this surgical modality was not addressed. Additionally, despite the large sample size, these patients were treated at a single institution, which may affect the generalizability of these findings. The increased risk for any transfusion based on a clopidogrel stop interval of 4-5 days remains unexplained in our cohort. Information about the use of anticoagulants was not available in this study, nor were the rates of postoperative myocardial infarction and cerebrovascular accidents. Although neither are used routinely at our centre, as their use increases, the optimal stop interval for ticagrelor and prasugrel remains an area for future study.

Conclusions

The administration of clopidogrel 1-2 days before surgery increases the risk for major bleeding outcomes, prolonged ventilation, and mortality, and should be avoided. Administration of clopidogrel 3-4 days before surgery was not associated with an increased risk for major transfusions or hemorrhagic complications, and this stop interval allows for more timely surgical intervention than the 5-day stop interval recommended by current guidelines.

Acknowledgements

The authors acknowledge the invaluable support of Mr Bryan Crocker, Manager Pathology and Lab Medicine, Nova Scotia Health, and Dr Calvino Cheng, Informatics Director, Department of Pathology and Lab Medicine, Dalhousie University, for the preparation of lab data for analysis in our article.

Funding Sources

This study was funded by the Dalhousie Medical Research Foundation & the Faculty of Medicine through the Hoegg Summer Research Studentship. The study funders were not involved with the project pertaining to study design, data collection, analysis, interpretation of the data, or preparation or approval of the article, or the decision to submit it for publication.

Disclosures

The authors have no conflicts of interest to disclose.

References

1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-5.
4. Parikh SV, de Lemos JA, Jessen ME, et al. Timing of in-hospital coronary artery bypass graft surgery for non–ST-segment elevation myocardial infarction patients. JACC Cardiovasc Interv 2010;3:419-27.
5. Fox KAA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non–ST-elevation acute coronary syndrome. Circulation 2004;110:1202-8.
6. Seese L, Sultan I, Gleason TG, et al. The impact of preoperative clopidogrel on outcomes after coronary artery bypass grafting. Ann Thorac Surg 2019;108:1114-20.
7. Berger JS, Frye CB, Harshaw Q, et al. Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery. A multicenter analysis. J Am Coll Cardiol 2008;52:1693-701.
8. Biancari F, Airaksinen KEJ, Lip GYH. Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. J Thorac Cardiovasc Surg 2012;143:665-675.e4.
9. Firanesce CE, Martens EJ, Schonberger JP, Soliman Hamad MA, van Straten AH. Postoperative blood loss in patients undergoing coronary artery bypass surgery after preoperative treatment with clopidogrel. A prospective randomised controlled study. Eur J Cardiothorac Surg 2009;36:856-62.
10. Vorobcsuk A, Aradi D, Farkasfalvi K, Horvath IG, Komocsi A. Outcomes of patients receiving clopidogrel prior to cardiac surgery. Int J Cardiol 2012;156:34-40.
11. Weidinger F. Discontinuation of P2Y12 antagonists before coronary bypass surgery: Is 5 days really required? Eur Heart J 2016;37:198-9.
12. Herman CR, Burh KJ, Kent B a, et al. Clopidogrel increases blood transfusion and hemorrhagic complications in patients undergoing cardiac surgery. Ann Thorac Surg 2010;89:397-402.
13. Chu MWA, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004;78:1536-41.
14. Leong J, Baker RA, Shah PJ, Cherian VK, Knight JL. Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg 2005;80:928-33.
15. Mehta SR, Bainey KR, Cantor WJ, et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused
update of the guidelines for the use of antiplatelet therapy. Can J Cardiol 2018;34:214-33.

16. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg 2018;53:34-78.

17. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. J Am Coll Cardiol 2011;58: e123-210.

18. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130:2354-94.

19. Kim JHJ, Newby LK, Clare RM, et al. Clopidogrel use and bleeding after coronary artery bypass graft surgery. Am Heart J 2008;156:886-92.

20. Mehta RH, Roe MT, Mulgund J, et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 2006;48:281-6.

21. Hansson EC, Jidéus L, Åberg B, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J 2016;37:189-97.

22. Stanworth SJ, Morris TP, Gaarder C, et al. Reappraising the concept of massive transfusion in trauma. Crit Care 2010;14:R239.

23. Delaney M, Stark PC, Suh M, et al. Massive transfusion in cardiac surgery: the impact of blood component ratios on clinical outcomes and survival. Anesth Analg 2017;124:1777-82.

24. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;64:e139-228.

25. Held C, Senblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol 2011;57:672-84.

26. Hongo RH, Ley J, Dick SE, Yee RR. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass surgery. J Am Coll Cardiol 2002;40:231-7.

27. Ebrahimi R, Dyke C, Mehran R, et al. Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery. The ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) Trial. J Am Coll Cardiol 2009;53:1965-72.

28. Ascione R, Ghosh A, Rogers CA, et al. In-hospital patients exposed to clopidogrel before coronary artery bypass graft surgery: a word of caution. Ann Thorac Surg 2005;79:1210-6.

29. Mehta RH, Sheng S, O’Brien SM, et al. Reoperation for bleeding in patients undergoing coronary artery bypass surgery. Circ Cardiovasc Qual Outcomes 2009;2:583-90.